Ryan. Thanks,
was a operational productive period perspective. highly quarter second an from The
programs existing and pursue aggressively multiple to win expand new well customers. continued we quarter, the with business as as During
line as our to compliant maintenance of serialization business, an successfully our well addition it packaging was standards. In and normal with make upgrade that of course the also as Company aggregation executed to required shutdown, new a scheduled
products from the manufacture without beyond not expand to market. finally, period for work secured And Schedule Agency License our X the recently was to Substance Controlled company will X Schedule Enforcement a that Manufacturing growing Drug the drug the psychedelic challenges. allow us Yet
we scheduled as XXXX to delta as As QX packaging InfectoPharm Teva line inventory result shutdown a revenues well build. reported, a Ryan delay versus revenue the decline XXXX recorded by QX in a of a as created revenue the due XXXX short-term
focus that in an decreases an Teva believe variances these However, that by year-end. largely revenues recovered to environment. both unfavorable These our couple will More issue these validate increase past of customers development the years. revenue and precommercial continue offset diversification we face to were for the of prior strategy revenues, be core offsets our been financing our fact than the typical is has an
year, a efforts customers, those challenges the by preservation of by several were projects hold or as cash on first-half of overall or funding placed the customers. either primarily result During delayed
And project while line normal that in than the in Despite be certain guidance CDMO these time rates revenue year-end affected. believe higher attrition our seeing of is top attributed amount that past are a to hurdles, this will the we directly financing business, not can environment. we do be at current the
million. XXXX revision. believe million we and XXXX EBITDA our to we between However, are EBITDA million had and $XX EBITDA $XX revising million. Today, $XX guided We that between guidance our $XX of a do requires full-year guidance to previously
that CDMO. funding, is capacity taken that guidance remain the many financing ready operations remain will and place company steps at to sectors, the It it Societal capabilities have solid will and correct, This today. proactive current balance the and execute companies important in life by financing biotech emphasize business faced the can the time attributed to continue temporary. to that will be science be and shift in hardships At our believe we fundamentals being the confident soon fortify that in And CDMO needed we secure clients. the for environment while our to to has customers sheet and our be talent, our the Societal
to our debt provide certain covenants with structure additional as the wait breathing our end, renegotiated To we us current this out with creditors company room and market. the recently
certain the Specifically, announcement. decision restructuring, our and mandatory to fixed certain defer minimum ratios. drove completed among charge reduce other week, payments, our previous coverage last terms payments, This liquidity lower which was new benefits, and reschedule earnings
outcome We secured. pleased and flexibility effort the additional the this are of very financial with
provide for on our I bit the quarter. would color like now to achievements more a
business of XX programs. new signed expanded we agreements scope quarter, for existing second the During and work
business the expanded sales we are our and the both gate. we by we and seeing also the of progress development During out leadership encouraged team period, our are
a order that our customers protect are Xequel to our Inc. able a not during programs signed in competitive While the the new period, majority including we highlight we disclose strategies, new their partnerships to do require Bio, with few project of
an services Societal corneal is CDMO of by aCTX process ongoing trial chemical of offerings, provide containing a of for platform. peptide support which aCTX of on spans sterile, to new range upcoming persistent manufacturing a is aCTX our the potential development services trials preservative placebo ophthalmic being clinical ophthalmic and Xequel Through Phase treatment in clinical compound its X including solution the development based will currently The cGMP a culminating defects. free is this for that of patented the entity clinical epithelial project, iNexin solution. iNexin, evaluated and agreement
including a proprietary batches. Selective Atossa's Therapeutics and on Modulator, analytical offerings R&D The stability period, method were range the validation, cleaning SERM focused batches, verification, of clinical manufacturing also testing and by activities agreement development Estrogen of we range of During (Z)-endoxifen. method Atossa engineering validation, transfer, multiple to selected the engineering spans trial a Receptor of services provide or R&D
signed to also expand drug agreement Service and with clinical development therapeutic transfer with of CivicaScript. an subsequent This to include programs Inc. registration Societal support covers candidate won through Master to the project initial of potential Biosciences, end, services a additional generic a project moving execute that a efforts finally, is Spinnaker novel quarter a Agreement the the to supporting CivicaScript of CDMO development We candidate. with and tech new supporting
process vials of this of cGMP testing agreement batch X/X include in be candidate sterile Phase to into to and planned transfer used manufacturer filling and prototype therapeutic analytical qualification, a The of under the powder therapeutic the a study. aseptic resultant conducted the activities stability method of be development,
to services and hope development of growing finish. We fill customer start projects manufacturing these I as finish and partner recognition to cGMP Societal broad a span to believe process of new stage highlights expand an capabilities CDMO growing effort in the this range we to markets. continue scope is As our a to evident, of early address
The manufacturing fit experience strategic The it manufacture Societal announced is step unique drug on license natural to substances. company expand handling has a development. and taken by that company well in to Schedule U.S. positions our X completed the company therapy decades to sector for our believe this a in planned substance recently expansion our Enforcement manufacturing number address Agency compounds We the certain it experience controlled to This and add as clinical that approval and well emerging received this announced regulatory area. as recently controlled requirements psychedelic has to trials Drug key growing a of ongoing psychedelic the securing of based support services another psychedelic of registration. in
These XX registration upon compounds Schedule expand held the DEA have that manufacturing with X we for years. the over
committing without its expand capabilities now development additional any drug to psychedelic Importantly, into able Societal the capital is market investment.
this We are to our in in with forward engaged new look drug leading space. area, manufacturers discussions and work exciting we psychedelic currently in the and
that operational would solid. and again In business the reiterate to like remain closing, I fundamentals company's
debt, last the for our have we sheet improved plans and Over our balance reduced our support covenants year, substantially strengthened growth. to our
impact to financing encouraged we end, continue to BD our and that we This sign environment sales to feed progress today's as both We work on to our pipeline, and are new of leadership as mitigate to continue well the have business, our to continues very they our group projects the expanded by team. make.
team forward the areas we range of in expanding to year, continues As we superb of customer meet look place, capabilities and of the and that new pipeline projects demand. a a grow to of strong have second-half a broad to
ahead. today's headwinds markets temporary In believe organization excel short, the is we weather well-positioned to in and financing our is
today. open my the call prepared questions. Operator? for now up can for concludes remarks This We
